MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-01
DOI
10.1186/s13045-020-0844-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
- (2019) Xuan Jiang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers
- (2019) Gayathri Srinivasan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2 -Mutated Carcinomas
- (2018) Khyati Meghani et al. Cell Reports
- Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
- (2018) Theo A. Knijnenburg et al. Cell Reports
- The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
- (2018) Jennifer Ma et al. Nature Communications
- Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids
- (2018) Sarah J. Hill et al. Cancer Discovery
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells
- (2018) Sabine Hombach-Klonisch et al. Molecular Oncology
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA therapy: Are we using the right molecules?
- (2018) Ai-Ming Yu et al. PHARMACOLOGY & THERAPEUTICS
- Therapeutic targeting and patient selection for cancers with homologous recombination defects
- (2017) Francien Talens et al. Expert Opinion on Drug Discovery
- RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
- (2017) Mariam Gachechiladze et al. INTERNATIONAL JOURNAL OF CANCER
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
- (2017) Rajesha Rupaimoole et al. NATURE REVIEWS DRUG DISCOVERY
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Optimal primary therapy of ovarian cancer: Table 1.
- (2016) M. A. Bookman ANNALS OF ONCOLOGY
- A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
- (2016) M. Makvandi et al. CANCER RESEARCH
- In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
- (2016) Mariam M. AlHilli et al. GYNECOLOGIC ONCOLOGY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
- (2015) Guoyan Liu et al. JNCI-Journal of the National Cancer Institute
- HMGA2 Inhibits Apoptosis through Interaction with ATR-CHK1 Signaling Complex in Human Cancer Cells
- (2015) Suchitra Natarajan et al. NEOPLASIA
- Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition
- (2013) Kenji Sakogawa et al. CANCER SCIENCE
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
- (2013) Kathryn P. Pennington et al. CLINICAL CANCER RESEARCH
- miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition
- (2013) Chaoyang Sun et al. JNCI-Journal of the National Cancer Institute
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
- (2012) Z. C. Wang et al. CLINICAL CANCER RESEARCH
- Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
- (2011) Karen A Gelmon et al. LANCET ONCOLOGY
- Germline mutations in RAD51D confer susceptibility to ovarian cancer
- (2011) Chey Loveday et al. NATURE GENETICS
- HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents
- (2011) D Palmieri et al. ONCOGENE
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
- (2011) T. Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients
- (2010) M. A. Vollebergh et al. ANNALS OF ONCOLOGY
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
- (2010) Patryk Moskwa et al. MOLECULAR CELL
- DEGseq: an R package for identifying differentially expressed genes from RNA-seq data
- (2009) Likun Wang et al. BIOINFORMATICS
- Suppression of Nonhomologous End Joining Repair by Overexpression of HMGA2
- (2009) A. Y.J. Li et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More